Darolutamide well tolerated in patients with nmCRPC who have comorbidities

“[These favorable findings just speak] to the complexity of the health index for these patients,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the background and findings of the study, “Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.